PhotoLiB · Photoswitchable amphiphilic lipids: a photopharmacology strategy to combat drug-resistant bacterial infections.

Photoswitchable amphiphilic lipids: a photopharmacology strategy to combat drug-resistant bacterial infections.

The research conducted in this fellowship has successfully addressed a critical issue in antibiotic development—the rapid adaptation of bacteria to external stresses, including antibiotics, and their ability to develop robust defense mechanisms. Our proposed solution involved a novel approach: targeting bacterial membranes and cell walls. Unlike modifiable proteins and enzymes, these structural elements resist alteration, leading to the effective elimination of bacteria. In response to the escalating concern over antibiotic resistance, our research introduced an innovative strategy that combines photopharmacology principles with membrane-disrupting drugs. The core concept involved connecting cationic amphiphilic molecules with photoswitchable probes to modulate drug mobility and activity. This enhanced selectivity and accelerated bacterial membrane disruption. The primary objectives of the research were successfully achieved: (1) developing new antibacterial drugs, Photoswitchable Amphiphilic Lipids (PALs), which interact with and disrupt bacterial membranes and cell walls upon light activation; (2) identifying PALs capable of disrupting bacterial membranes at different wavelengths, providing versatility; (3) exploring synergistic effects of PALs when combined with standard antibiotics to amplify antibiotic efficacy. The compounds devised during the fellowship represent a unique approach where light serves as a modulator, employing a switch-on/off strategy to regulate their activity. This innovative mechanism enables the selective targeting of Gram-positive bacteria, minimizing exposure time and mitigating the risk of resistance development. The implications of this research point towards a groundbreaking strategy for the development of antibiotics with increased efficacy and reduced potential for resistance. This research significantly aligns with the European research priority of "Antimicrobial Resistance," addressing a critical global health challenge. It transcends geographical boundaries and contributes to global public health, while also aligning with the objectives of European Health Systems and the interests of European industries. It establishes a crucial research foundation for innovative strategies and therapies against drug-resistant bacterial infections, enhancing healthcare practices, patient outcomes, and industry competitiveness. In conclusion, this research goes beyond academia, offering real-world solutions aligned with European health priorities and the imperative for novel therapeutic strategies. The project has made a substantive and enduring contribution to the broader health landscape, particularly in the ongoing battle against antibiotic-resistant bacterial strains.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз